Dr Paul Brooker

Paul studied Biological Sciences at the University of East Anglia before moving to University College, London where he completed a PhD in Genetics, working on cytogenetic variation in British house mice. Following postgraduate work he moved into industry, working for 33 years  at Envigo, Europe’s largest pre-clinical contract research organisation. Beginning his work in the genetic toxicology group, Paul moved on to other scientific, commercial and leadership positions within the company, including that of Director of Toxicology, before finally taking up the role of President, EMEA (Europe, Middle East and Asia Pacific), where he carried responsibility for all of the scientific and breeding operations of Envigo across its 28 EMEA sites, involving over 3000 scientific and technical staff and disciplines ranging from toxicology, pharmacology and pathology to environmental sciences and various chemistry and biochemistry groups and animal breeding. He retired from Envigo in October 2016. Paul has published papers on a variety of subjects, including evolutionary genetics, genetic toxicology, in vitro alternatives to animal studies and global regulatory requirements. He was for ten years a member and for three years the Chair of the pre-clinical drug safety advisory group of the Association of the British Pharmaceutical industry (ABPI). He is a member of Council of the Royal Society of Biology, and is a member of the Board of the NC3Rs.